A simple novel prognostic model for early stage oral tongue cancer. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Almangush, A.; Coletta, R.D.; Bello, I.O.; Bitu, C.; Keski-Säntti, H.; Mäkinen, L.K.; Kauppila, J.H.; Pukkila, M.; Hagström, J.; Laranne, J.; Tommola, S.; Soini, Y.; Kosma, V.-M.; Koivunen, P.; Kowalski, L.P.; Nieminen, P.; Grénman, R.; Leivo, I.; Salo, T.
• Is Part Of: International journal of oral & maxillofacial surgery. Volume 44:Issue 2(2015:Feb.)
• Page Start: 143
• Page End: 150
• Publication Date: 2015-02
• Subjects: Mouth -- Surgery -- Periodicals; Maxilla -- Surgery -- Periodicals; Dentistry -- Periodicals; Dentistry, Operative; Oral Surgical Procedures; Surgery, Oral; Dentistry; Maxilla -- Surgery; Mouth -- Surgery; Electronic journals; Periodicals; 617.52059
• DOI: 10.1016/j.ijom.2014.10.004
• Languages: English
• ISSNs: 0901-5027

Abstract

<abstract abstract-type="author" id="abs0005"> <title id="sect0005">Abstract</title> <sec> <p id="spar0005">The prognostication of patient outcome is one of the greatest challenges in the management of early stage oral tongue squamous cell carcinoma (OTSCC). This study introduces a simple histopathological model for the prognostication of survival in patients with early OTSCC. A total of 311 cases (from Finland and Brazil) with clinically evaluated early stage OTSCC (cT1–T2cN0cM0) were included in this multicentre retrospective study. Tumour budding (B) and depth of invasion (D) were scored on haematoxylin–eosin-stained cancer slides. The cut-off point for tumour budding was set at 5 buds (low &lt;5; high ≥5) and for depth of invasion at 4 mm (low &lt;4 mm; high ≥4 mm). The scores of B and D were combined into one model: the BD predictive model. On multivariate analysis, a high risk score (BD score 2) correlated significantly with loco-regional recurrence (<italic>P</italic> = 0.033) and death due to OTSCC (<italic>P</italic> &lt; 0.001) in early stage OTSCC. The new BD model is a promising prognostic tool to identify those patients with aggressive cases of early stage OTSCC who might benefit from multimodality treatment.</p> </sec> </abstract>